Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9313086 | 0.83 | — | — | |
| SCHEMBL712819 | 0.78 | TSHR (0.30) | — | |
| SCHEMBL20299840 | 0.74 | SLC1A2 (0.41) | — | |
| SCHEMBL20299839 | 0.74 | SLC1A2 (0.41) | — | |
| SCHEMBL3384488 | 0.73 | CYP3A4 (0.38) | ALDH1A1RAB9A | |
| SCHEMBL2160390 | 0.71 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL712733 | 0.71 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL9840033 | 0.69 | — | — | |
| SCHEMBL6848903 | 0.68 | TSHR (0.42) | — | |
| SCHEMBL18526694 | 0.68 | ALDH1A1 (0.37) | TP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2663311-A2 | PYRIMIDINONE DERIVATIVES AS FATTY ACID SYNTHASE INHIBITORS | GlaxoSmithKline LLC (US) | 2013-11-20 | — | — | EP | disclosed |
| US-20130303551-A1 | PYRIMIDINONE DERIVATIVES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2013-11-14 | — | — | US | disclosed |
| US-20130303551-A1 | PYRIMIDINONE DERIVATIVES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2013-11-14 | — | — | US | disclosed |
| WO-2012096928-A2 | PYRIMIDINONE DERIVATIVES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-07-19 | — | — | WO | disclosed |
| EP-1615897-B1 | PYRIMIDINONE COMPOUNDS AS CALCILYTICS | NPS PHARMA INC (US) | 2010-11-24 | — | — | EP | disclosed |
| EP-1615897-B1 | PYRIMIDINONE COMPOUNDS AS CALCILYTICS | NPS PHARMA INC (US) | 2010-11-24 | — | — | EP | disclosed |
| US-7491728-B2 | Pyrimidinone compounds as calcilytics | SMITHKLINE BEECHAM CORP. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7491728-B2 | Pyrimidinone compounds as calcilytics | SMITHKLINE BEECHAM CORP. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7491728-B2 | Pyrimidinone compounds as calcilytics | SMITHKLINE BEECHAM CORP. (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1613606-A4 | METHODS FOR PREPARING 2,3,5,6-SUBSTITUTED 3H-PYRIMIDIN-4-ONES | NPS PHARMA INC (US) | 2008-12-03 | — | — | EP | disclosed |
| US-20070197555-A1 | Pyrimidinone Compounds As Calcilytics | GLAXOSMITHKLINE LLC | 2007-08-23 | — | — | US | disclosed |
| US-20070197555-A1 | Pyrimidinone Compounds As Calcilytics | GLAXOSMITHKLINE LLC | 2007-08-23 | — | — | US | disclosed |
| US-20070161792-A1 | Methods for preparing 2,3,5,6-substituted 3h-pyrimidin-4-ones | NPS PHARMACUETICALS, INC (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161792-A1 | Methods for preparing 2,3,5,6-substituted 3h-pyrimidin-4-ones | NPS PHARMACUETICALS, INC (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161792-A1 | Methods for preparing 2,3,5,6-substituted 3h-pyrimidin-4-ones | NPS PHARMACUETICALS, INC (US) | 2007-07-12 | — | — | US | disclosed |
| CN-1835928-A | Pyrimidone compounds as calcium-sensitive receptor antagonists | NPS PHARMA INC (US) | 2006-09-20 | — | — | CN | disclosed |
| EP-1615897-A2 | PYRIMIDINONE COMPOUNDS AS CALCILYTICS | NPS PHARMACEUTICALS, INC. (US) | 2006-01-18 | — | — | EP | disclosed |
| EP-1613606-A2 | METHODS FOR PREPARING 2,3,5,6-SUBSTITUTED 3H-PYRIMIDIN-4-ONES | NPS PHARMACEUTICALS, INC. (US) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004092121-A2 | METHODS FOR PREPARING 2,3,5,6-SUBSTITUTED 3H-PYRIMIDIN-4-ONES | NPS PHARMACEUTICALS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004092120-A2 | PYRIMIDINONE COMPOUNDS AS CALCILYTICS | NPS PHARMACEUTICALS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303551-A1 | PYRIMIDINONE DERIVATIVES AS FATTY ACID SYNTHASE INHIBITORS | FASN, FPGS, DHPS | TP53 1789/4885ALDH1A1 349/4885RAB9A 3671/4885 |
| US-20070197555-A1 | Pyrimidinone Compounds As Calcilytics | TYMP, DPYD, UMPS | TP53 3842/4885ALDH1A1 2151/4885RAB9A 1814/4885 |
| US-20070161792-A1 | Methods for preparing 2,3,5,6-substituted 3h-pyrimidin-4-ones | TYMP, DPYD, DHFR | TP53 3248/4885ALDH1A1 972/4885RAB9A 3220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.